patients suffering from chronic autoimmune thrombocytopenia the platelet function/activation will be investigated the rise of reticulated platelets and variation of platelet antibodies will be investigated
Conditions
Sponsors
Medizinische Universität Wien, Universitätsklinik Innere Medizin I
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria for all groups - Male and female patients with an established chronic autoimmune thrombocytopenia (cAITP) - Age = 18 and 90=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - History of venous or arterial thromboembolism or stroke - Known coronary heart disease or cardiac arrythmias - Known HIV or Hepatitis C infection - Impaired liver function defined as elevated ALT > 1.5 UNL, Bilirubin more than ULN, Albumin less than normal value - Prothrombin time less than normal value - Elevated creatinine level (> 1.3 ULN) - Unable/unwilling to follow protocol - Previous or active malignancy - Patients who have been included in any other study with Elthrombopag any time before - Patients treated with another investigational product within the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine the effect of the new treatment option on high shear-induced platelet activation, and shear independent platelet activation in patients with cAITP. In vitro addition of agonists shall allow to estimated the functional capacity of platelets. ;Secondary Objective: The rise of reticulated platelets and variation of platelet antibodies shall be docmented.;Primary end point(s): to determine the shear-induced platelet activation to estimate the functional capacity of platelets | — |
Countries
Austria
Outcome results
None listed